Spectrum Pharmaceuticals (Nasdaq:SPPI) - Aandelenkoers, Nieuws & Analyse

SPPI Overzicht aandelen

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. Meer informatie

SPPI fundamentele analyse
Sneeuwvlok Score
Waardering	6/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	0/6

Beloningen

Verhandeld tegen 82.9% onder onze schatting van de reële waarde

De winst zal naar verwachting met 67.27% per jaar groeien

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Analisten zijn het erover eens dat de aandelenkoers met 22.3% zal stijgen

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar verwaterd

Heeft minder dan 1 jaar cash runway

Spectrum Pharmaceuticals, Inc. Concurrenten

Gossamer Bio

NasdaqGS:GOSS

US$157.6m

Pyxis Oncology

NasdaqGS:PYXS

US$227.2m

Zentalis Pharmaceuticals

NasdaqGM:ZNTL

US$223.1m

Invivyd

NasdaqGM:IVVD

US$91.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Spectrum Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$1.03
52 Week Hoogtepunt	US$1.57
52 Week Laag	US$0.32
Bèta	2.14
11 maand verandering	4.54%
3 maanden verandering	-1.90%
1 Jaar Verandering	17.05%
33 jaar verandering	-71.39%
5 jaar verandering	-95.10%
Verandering sinds IPO	-99.25%

Recent nieuws en updates

Recent updates

Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

May 14

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

May 12

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

Sep 20

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

Sep 16

Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

Sep 09

Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'

Aug 21

Spectrum Pharmaceuticals Q2 2022 Earnings Preview

Aug 10

Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Jun 04

Spectrum Pharmaceuticals: Some Last Words

Feb 25

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Oct 05

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

May 31

We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate

Feb 12

Spectrum Pharma drops after announcing less-than-favorable Phase 2 data

Dec 22

Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like

Dec 21

Spectrum Pharma Is Down But Not Out

Nov 16

Spectrum Shareholders In Limbo As FDA Delays Rolontis Decision Date, Agrees To Discuss Poziotinib

Nov 11

Rendement voor aandeelhouders

	SPPI	US Biotechs	US Markt
7D	5.3%	-3.7%	0.3%
1Y	17.0%	15.2%	31.1%

Rendement versus industrie: SPPI overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 15.2 % opleverde.

Rendement versus markt: SPPI overtrof de US markt, die het afgelopen jaar een rendement opleverde van 31.1 %.

Prijsvolatiliteit

Is SPPI's price volatile compared to industry and market?
SPPI volatility
SPPI Average Weekly Movement	7.2%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van SPPI is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van SPPI is het afgelopen jaar gedaald van 15% naar 7%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1987	86	Tom Riga	www.sppirx.com

Spectrum Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Spectrum Pharmaceuticals zich tot de beurswaarde?
SPPI fundamentele statistieken
Marktkapitalisatie	US$209.89m
Inkomsten(TTM)	-US$67.71m
Inkomsten(TTM)	US$25.73m

8.2x

P/S-verhouding

-3.1x

Koers/Winstverhouding

Is SPPI overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SPPI resultatenrekening (TTM)
Inkomsten	US$25.73m
Kosten van inkomsten	US$2.86m
Brutowinst	US$22.87m
Overige uitgaven	US$90.58m
Inkomsten	-US$67.71m

Laatst gerapporteerde inkomsten

Mar 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.33
Brutomarge	88.90%
Nettowinstmarge	-263.16%
Schuld/Eigen Vermogen Verhouding	107.6%

Hoe presteerde SPPI op de lange termijn?

Bekijk historische prestaties en vergelijking

SPPI Overzicht aandelen

Beloningen

Risicoanalyse

Spectrum Pharmaceuticals, Inc. Concurrenten

NasdaqGS:GOSS

US$157.6m

NasdaqGS:PYXS

US$227.2m

NasdaqGM:ZNTL

US$223.1m

NasdaqGM:IVVD

US$91.9m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Spectrum Pharmaceuticals, Inc. Files Form 15

Spectrum Pharmaceuticals, Inc.(NasdaqCM:SPPI) dropped from NASDAQ Composite Index

Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).

Consensus estimates of losses per share improve by 38%

Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 23%

Recent updates

Spectrum Pharmaceuticals, Inc. Files Form 15

Spectrum Pharmaceuticals, Inc.(NasdaqCM:SPPI) dropped from NASDAQ Composite Index

Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).

Consensus estimates of losses per share improve by 38%

Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 23%

Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

Price target decreased by 33% to US$1.26

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

Forecast breakeven date moved forward to 2024

Consensus EPS estimates upgraded to US$0.17 loss

Price target decreased by 15% to US$2.65

Spectrum Pharmaceuticals, Inc. Receives Permanent J-Code for ROLVEDON Injection (J1449) from U.S. Centers for Medicare & Medicaid Services

President notifies of intention to sell stock

Consensus revenue estimates increase by 161%

Spectrum Pharmaceuticals, Inc. Provides Sales Guidance for the Quarter Ended December 31, 2022

Spectrum Pharmaceuticals Announces Executive Changes

Forecast to breakeven in 2025

Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Spectrum Pharmaceuticals, Inc

Spectrum Pharmaceuticals’ ROLVEDON™ Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors

Consensus revenue estimates increase by 16%

Spectrum Pharmaceuticals, Inc. Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection

Price target decreased to US$3.10

Price target decreased to US$4.13

Spectrum Pharmaceuticals Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Spectrum Pharmaceuticals Announces Commercial Availability of Rolvedon™ (Eflapegrastim-Xnst) Injection

No longer forecast to breakeven

Spectrum Pharmaceuticals, Inc. Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting

Price target decreased to US$5.40

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

Consensus forecasts updated

Spectrum Pharmaceuticals Receives Food and Drug Administration Approval for ROLVEDON (eflapegrastim-xnst) Injection

Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'

Consensus revenue estimates fall by 61%

Spectrum Pharmaceuticals Q2 2022 Earnings Preview

Spectrum Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Consensus forecasts updated

Spectrum Pharmaceuticals, Inc. Appoints Nora E. Brennan as Chief Financial Officer

Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to its Board of Directors

Price target decreased to US$5.60

Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim

Price target decreased to US$5.60

Spectrum Pharmaceuticals: Some Last Words

Spectrum Pharmaceuticals, Inc. Announces Resignation of Kurt Gustafson as Chief Financial Officer

Spectrum Pharmaceuticals, Inc. Announces Acceptance of New Drug Application Filing for Poziotinib

Spectrum Pharmaceuticals Announces Strategic Restructuring

Forecast to breakeven in 2024

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Spectrum Pharmaceuticals, Inc. Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at European Society for Medical Oncology Congress 2021

Pomerantz LLP Announces the Filing of Class Action Against Spectrum Pharmaceuticals, Inc and Certain Officers

Consensus revenue estimates fall to US$2.30m

Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity

Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for ROLONTIS® (eflapegrastim)

No longer forecast to breakeven

Price target decreased to US$9.40

High number of new directors